Creative Biolabs have developed a wide spectrum of T cell antigen connector (TAC)-engineered T cell services, ranging from TAC design and construction, TAC-cell gene delivery selection, TAC-T cell production, and characterization. We will help to tailor the suitable research protocols and provide the best project development solutions, aiming to bring new therapies to market with the lowest risk and cost. You can learn more about our platform technology, or apply for a quote.
TAC-T cells are unique autologous or allogeneic T cells that express antigens to tumor cells. The design of the TAC construction element, the activation pathway of T cells induced by TAC, in vitro culture conditions, and host T cell types all have a great influence on the efficacy and safety of TAC-T. Therefore, data from in vivo trials are valuable for further TAC optimization. Using our TAC cell product portfolio, in vivo model, and TAC cell therapy assay, our team can customize a comprehensive set of pharmacological and safety studies to meet your TAC's cellular immunotherapy needs. We will help you navigate complex application issues and collect high-quality data to accelerate your R&D path.
The validation of TAC-T cells cannot only simulate the safety and complexity issues faced in clinical trials through a single animal tumor model. However, our existing TAC model data show that these models can provide an important basis for predicting the dose of TAC-T cells, tumor loading, signal potency, and toxic and side effects.
The in vivo TAC models can be used to evaluate the TAC-engineered T-cell functions and examined their potential to predict TAC-T-cell-driven toxicities in the future. In our platform, we have established a variety of animal models, including mice, rats, rabbits, dogs, goats, cattle, chickens, and other non-human primates to meet your requirement. Meanwhile. a strict detection system has been applied to evaluate the reproducibility and specialty of TAC -T models.
Fig.1 TAC In Vivo Analysis Assay Services.
TAC-engineered T-cell therapy has proven its success in treating hematological malignancies and solid tumors. In vivo efficacy tests of TAC-T cells in different tumor models are critical to the application of TAC technology in the clinic. Some of the solutions we have developed include:
Fig.2 Toxicity and Anti-Tumor Activity Analysis of CD19-TAC T Cells in Murine Xenograft Model.
Our in vivo assay is designed to assess the various aspects of the interaction between disease-related TAC-T cells and the immune system. We offer toxicity evaluation on various animal tumor models and test the serum cytokine toxicity in TAC-T cells as well as the expression of target antigens on normal cells. The safety profile of TAC-T cells would provide evidence for making TAC therapy accessible for clinical application.
Fig.3 Comparison of Transduction Efficiency of CD19-TAC T Cells and Blank Control T Cells on Day 14 by Flow cytometry.
Fig.4 In Vivo Assessment of Anti-Tumor Efficacy of BCMA-TAC (TAC-001) and CD19-TAC (TAC-002).
For more than decades, Creative Biolabs has served clients in cell therapy academia and industry around the world. With our commitment to quality, we will work closely with you to provide the best in vivo TAC analysis services that meet your precise specifications. We offer cutting-edge technology platforms, excellent service, fast time, a large number of disease animal models for TAC research, and a 100% satisfaction guarantee. Now, we can provide many flexible in vivo assays aiming at showing efficacy and safety, from which you can always find a better match for your project. Please feel free to contact us for more information.
For Research Use Only
